UPDATE: Boston Scientific gets in the high blood pressure game with $425M Vessix deal

November 8, 2012 by MassDevice staff

Boston Scientific agrees to pay up to $425 million for Vessix and its renal denervation treatment for high blood pressure, jumping into the renal denervation race alongside rivals St. Jude Medical and Medtronic and largely pulling the plug on its internal renal denervation program.

Boston Scientific acquires Vessix

UPDATED Nov. 8, 2012, 11:15 a.m. with additional comments from Boston Scientific

Get the complete picture with a MassDevice Plus membership. Registered users can login here.